Recon: Allergan to Sell Women’s Health and Infectious Disease Units

• AstraZeneca drug Fasenra fails to achieve main goal in COPD trial (Reuters) (Endpoints) (The Pharma Letter-) (GEN) (pharmaphorum) (BioPharma Dive)
• Allergan to sell women's health and infectious disease units after strategic review: Sources (CNBC) (Reuters) (Financial Times)
• FDA expands approval of Pfizer Xeljanz (FDA)
• Novo's oral semaglutide bests Lilly and Boehringer Ingelheim's Jardiance in phase 3, but questions remain (Fierce) (Endpoints) (PharmaTimes) (The Pharma Letter-$) (Reuters)
• Priority review for Astellas’ AML drug (PharmaTimes) (Rare Disease Report)
• On second try, TherapeuticsMD lands FDA nod for vaginal capsule (Drug Delivery Business News) (Reuters) (BioPharma Dive) (Endpoints)
• Out of the FDA doghouse, Celltrion again seeks Rituxan biosimilar nod (Fierce) (The Korea Herald) (BioPharma-Reporter)
• FDA moves Sage’s postpartum depression drug brexanolone into regulators’ busy priority lane (Endpoints) (Drug Delivery Business News) (Fierce)

• Chinese regulator clears Gilead’s newest hepatitis C drug (The Pharma Letter-$) (Fierce)
• Ugandan Makes Africa Prize Finals With Innovative Malaria Detection Device (East African Business Week) (Africa Science News Service)
• Trial to test new treatment combination for children and adults with leukaemia (Cancer Research UK) (PharmaTimes)
• NHS England invests £10m in bid to keep new GPs from leaving profession (Pulse) (Pharmafile) (National Health Executive) (PharmaTimes)
• Crescendo cuts psoriasis drug deal with China’s Zai Labs (Fierce)
• Why Egypt Is at the Forefront of Hepatitis C Treatment (The Atlantic)
• China overtakes U.S. for healthy lifespan: WHO data (Reuters)
• Gap in regulating biotech drug copies prompts WHO to step in (Reuters)
• Ebola outbreak opens way to chaotic jockeying to test experimental drugs (STAT)
• Australian contribution to fighting Ebola and other infectious disease outbreaks (Government of Australia)

• Why Some Patients Getting Drugmakers' Help Are Paying More (NPR)
• Drugmakers struggle to find immunotherapy combinations for cancer (Financial Times)
• Failed Bush-era drug-pricing program may make more sense under Trump (Politico)
• Right-To-Try Doesn’t Help Patients, Hurts FDA, Drugmakers (Bloomberg)
• A Glioblastoma Vaccine? Not Yet. (Science Magazine)
• Ipsen and MD Anderson agree deal on promising cancer candidate (The Pharma Letter) (Press)
• Biologics and Biosimilars Collective Intelligence Consortium Quarterly: Letter from the program director (BBCIC)
• Sanofi’s internal memo after a subpoena illustrates concerns over MS drug marketing (STAT-$)
• With $20 Million In Funding, Propeller Health Partners With Aptar Pharma To Make Digital Medicines (Forbes)
• Investors Anxious To See Walgreens U.S. Drugstore Of The Future (Forbes)
• Venter to leave Human Longevity as turnover at the top continues (Fierce)
• Daiichi Sankyo US subsidiary, Luitpold Pharma to merge with its own subsidiaries (Pharmabiz)

• J&J hustles Legend’s promising BCMA CAR-T into PhI/II trial, winning an FDA green light to begin recruiting patients (Endpoints) (Press)
• List of 2018 Medicines in Development for Cancer (PhRMA)
• Are Big Clinical Trials Relevant? Researchers Disagree (WSJ)
• Alzheimer's: Rethinking the 'One-Size-Fits-All' Approach (MedPage Today)
• Xenon – P1 data provide more de-risking (Open Reading Frame)
• Northwest Bio's long-awaited glioblastoma vaccine data see stock roller coaster (Fierce)

• ResMed to acquire home and hospice software dev HealthcareFirst (MassDevice)
• Neurent cleans up $11M to fund in-office runny nose treatment (Fierce)
• Saranas raises $2.8M to pilot its internal bleeding detector (Fierce)
• Titan, Braeburn end licensing deal for implanted drug for opioid addicts (Fierce)
• Genetic Privacy, Disease Prevention, and the Principle of Rescue (Wiley Online Library)
• LifeCell launches prenatal test to detect genetic abnormalities in fetus (Pharmabiz)
• AI Versus Dermatologists At Diagnosing Skin Cancer, Here Are The Results (Forbes)
• Can This Bracelet Prevent Pregnancy? $30 Million Says Yes, Expert Not So Sure (Forbes)
• DNA donors must demand stronger protection for genetic privacy (STAT)
• K2M Receives FDA Clearance for BACS Patient-Specific Module (Press)

• Courts criticize cuts to HHS' teen pregnancy program (Axios)
• WellCare To Buy Meridian Health Plans And PBM For $2.5 Billion (Forbes)
• Hurricane Maria's death toll could exceed 4,600, study estimates (CNBC)
• GAO Makes MedPAC Appointments (GAO)
• Big Data and Predictive Analytics: Recalibrating Expectations (JAMA)
• The Cost of Prescription Drugs: Examining the President’s Blueprint ‘American Patients First’ to Lower Drug Prices (Senate HELP Committee)
• Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FDA)

• FDA Advisory Committee Calendar

• More than 1 million patients forced to get a new GP after seven-fold rise in practice closures (The Telegraph)
• Head of Sandoz UK becomes BGMA chair (Pharmafile)
• EU regulatory data protection - UK court considers generics’ challenges to prior EC decisions authorising reference product (Lexology-$)
• UK scientists first to 3D-print human corneas (Verdict Medical Devices)
• NHS Wales Securely Open for Business - the Vault workspace for commercially sensitive information (ABPI)
• EU ministers endorse Commission’s plans for research cloud (EC)
• 12 applications for allocation of special funds related to medicinal cannabis (Danish Medicines Agency)
• Strength and Opportunity in 2017: The landscape of the medical technology and biopharmaceutical sectors in the UK (HM Government)
• Kent Imaging Announces CE Mark for New Multispectral Imaging Product, Kent's KD203 (Press)

• Nipah virus: Key facts (WHO)
• ‘Reprogrammed’ stem cells approved to mend human hearts for the first time (Nature)
• Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List (Pharma Japan)
• India-Indonesia sign 15 MoUs in fields of defence, railways, health (Economic Times)
• Why Southeast Asia’s ‘irrational’ use of antibiotics could lead to dire consequences (Southeast Asia Globe)

• India’s drug regulator expects to finalize new clinical trial rules in two months (Reuters)
• India's Hidden Infertility Struggles (The Diplomat)
• Indian pharma industry keen to adopt automation to transform operations going the digital way: Dr. Amit Biswas (Pharmabiz)
• Intuitive Surgical goes direct in India (MassDevice)
• Child health in India: 14 out of 20 states cut spending on key programmes (Business Standard)

• One doctor group beats all in raking in Big Pharma cash to fund events (The Sydney Morning Herald)
• CSL says Switzerland, Ireland are knocking on its door, but Canberra is absent (Australian Financial Review)
• The 'tech geek' helping launch 90-year-old Flying Doctors into digital age (The Guardian)

• Gonorrhea, other sexually transmitted infections on the rise in Canada (The Canadian Press)
• OPINION: Want health-care revenue? Make Canada a medical tourism destination (The Chronicle Herald)
• Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest (Press)
• PharmaBoardroom Releases 'Healthcare and Life Sciences Review Canada' May 2018 Pharma Report (Press)

• Brazil Extends National Flu Vaccination Program Until June 15th (The Rio Times)
• Director Renato Porto talks about the Brazilian regulatory environment (Anvisa)

• The main forces spurring health care mergers (Axios)
• Want to earn $10k per month? Join the “journals mafia” (Retraction Watch)
• Doctors Can Increase Vaccination Rates In Kids Using New Approach, Study Finds (Forbes)
• Cancer group says colon screening should start at 45, not 50 (STAT)
• Doctors can change vaccine-hesitant parents' minds by being persistent: study (Fierce)